Acid-β-glucosidase (GCase, EC3.2.1.45), the lysosomal enzyme which hydrolyzes the simple glycosphingolipid, glucosylceramide (GlcCer), is encoded by the GBA1 gene. Biallelic mutations in GBA1 cause the human inherited metabolic disorder, Gaucher disease (GD), in which GlcCer accumulates, while heterozygous GBA1 mutations are the highest genetic risk factor for Parkinson's disease (PD). Recombinant GCase (e.g., Cerezyme® ) is produced for use in enzyme replacement therapy for GD and is largely successful in relieving disease symptoms, except for the neurological symptoms observed in a subset of patients. As a first step toward developing an alternative to the recombinant human enzymes used to treat GD, we applied the PROSS stability-design algorithm to generate GCase variants with enhanced stability. One of the designs, containing 55 mutations compared to wild-type human GCase, exhibits improved secretion and thermal stability. Furthermore, the design has higher enzymatic activity than the clinically used human enzyme when incorporated into an AAV vector, resulting in a larger decrease in the accumulation of lipid substrates in cultured cells. Based on stability-design calculations, we also developed a machine learning-based approach to distinguish benign from deleterious (i.e., disease-causing) GBA1 mutations. This approach gave remarkably accurate predictions of the enzymatic activity of single-nucleotide polymorphisms in the GBA1 gene that are not currently associated with GD or PD. This latter approach could be applied to other diseases to determine risk factors in patients carrying rare mutations.

Department of Biomolecular Sciences Weizmann Institute of Science Rehovot Israel

Department of Brain Sciences Weizmann Institute of Science Rehovot Israel

Department of Chemical and Structural Biology Weizmann Institute of Science Rehovot Israel

Department of Life Sciences Core Facilities Weizmann Institute of Science Rehovot Israel

J Heyrovsky Institute of Physical Chemistry of the Czech Academy of Sciences Prague Czech Republic

Lysogene Neuilly sur Seine France

See more in PubMed

Futerman AH & van Meer G (2004) The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 5, 554-565.

Meikle PJ, Hopwood JJ, Clague AE & Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281, 249-254.

Futerman AH & Zimran A (2006) Gaucher Disease. 1st edn. Taylor and Francis Group, CRC Press, Boca Raton, FL.

Grabowski GA, Gaft S, Horowitz M & Kolodny EH (1990) Acid beta-glucosidase: enzymology and molecular biology of Gaucher disease. Crit Rev Biochem Mol Biol 25, 385-414.

Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372, 1263-1271.

Schiffman R, Fitzgibbon EJ, Harris C, DeVile C, Davies EH, Abel L, van Schaik IN, Benko W, Timmons M, Ries M et al. (2008) Randomized, controlled trial of miglustat in Gaucher's disease type 3. Ann Neurol 64, 514-522.

Shayman JA (2013) The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity? Trans Am Clin Climatol Assoc 124, 46-60.

Weinberg MS, Samulski RJ & McCown TJ (2013) Adeno-associated virus (AAV) gene therapy for neurological disease. Neuropharmacology 69, 82-88.

Cearley CN & Wolfe JH (2006) Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 13, 528-537.

Hocquemiller M, Giersch L, Audrain M, Parker S & Cartier N (2016) Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther 27, 478-496.

Massaro G, Hughes MP, Whaler SM, Wallom K-L, Priestman DA, Platt FM, Waddington SN & Rahim AA (2020) Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes. Hum Mol Genet 29, 1933-1949.

Berg-Fussman A, Grace ME, Ioannou Y & Grabowski GA (1993) Human acid β-glucosidase. N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity. J Biol Chem 268, 14861-14866.

Magliery TJ (2015) Protein stability: computation, sequence statistics, and new experimental methods. Curr Opin Struct Biol 33, 161-168.

Goldenzweig A, Goldsmith M, Hill SE, Gertman O, Laurino P, Ashani Y, Dym O, Unger T, Albeck S, Prilusky J et al. (2016) Automated structure- and sequence-based design of proteins for high bacterial expression and stability. Mol Cell 63, 337-346.

Goldenzweig A & Fleishman SJ (2018) Principles of protein stability and their application in computational design. Annu Rev Biochem 87, 105-129.

Campeotto I, Goldenzweig A, Davey J, Barfod L, Marshall JM, Silk SE, Wright KE, Draper SJ, Higgins MK & Fleishman SJ (2017) One-step design of a stable variant of the malaria invasion protein RH5 for use as a vaccine immunogen. Proc Natl Acad Sci USA 114, 998-1002.

Kriegel M, Wiederanders HJ, Alkhashrom S, Eichler J & Muller YA (2021) A PROSS-designed extensively mutated oestrogen receptor α variant displays enhanced thermal stability while retaining native allosteric regulation and structure. Sci Rep 11, 1-13.

Peleg Y, Vincentelli R, Collins BM, Chen KE, Livingstone EK, Weeratunga S, Leneva N, Guo Q, Remans K, Perez K et al. (2021) Community-wide experimental evaluation of the PROSS stability-design method. J Mol Biol 433, 1-14.

Redler RL, Das J, Diaz JR & Dokholyan NV (2016) Protein destabilization as a common factor in diverse inherited disorders. J Mol Evol 82, 11-16.

Yazar M & Özbek P (2021) In silico tools and approaches for the prediction of functional and structural effects of single-nucleotide polymorphisms on proteins: an expert review. OMICS 25, 23-37.

Manickam M, Ravanan P, Singh P & Talwar P (2014) In silico identification of genetic variants in glucocerebrosidase (GBA) gene involved in Gaucher's disease using multiple software tools. Front Genet 5, 1-10.

Abildgaard AB, Stein A, Nielsen SV, Schultz-Knudsen K, Papaleo E, Shrikhande A, Hoffmann ER, Bernstein I, Anne-Marie G, Takahashi M et al. (2019) Computational and cellular studies reveal structural destabilization and degradation of mlh1 variants in lynch syndrome. Elife 8, e49138.

Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A et al. (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361, 1651-1661.

Blumenreich S, Jenkins BJ, Barav OB, Milenkovic I & Futerman AH (2020) The lysosome and nonmotor symptoms: linking Parkinson's disease and lysosomal storage disorders. Mov Disord 35, 2150-2155.

Lieberman RL, D'Aquino JA, Ringe D & Petsko GA (2009) Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry 48, 4816-4827.

Mirdita M, Schütze K, Moriwaki Y, Heo L, Ovchinnikov S & Steinegger M (2022) ColabFold - Making protein folding accessible to all. Nat Methods 19, 679-682.

Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A et al. (2021) Highly accurate protein structure prediction with AlphaFold. Nature 596, 583-589.

Dvir H, Harel M, McCarthy AA, Toker L, Silman I, Futerman AH & Sussman JL (2003) X-ray structure of human acid-β-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep 4, 704-709.

Beutler E, Gelbart T, Kuhl W, Zimran A & West C (1992) Mutations in Jewish patients with Gaucher disease. Blood 79, 1662-1666.

Cabrera-Salazar MA, Deriso M, Bercury SD, Li L & Lydon JT (2012) Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS ONE 7, e43310.

Ransohoff RM & Engelhardt B (2012) The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 12, 623-635.

Ron I & Horowitz M (2005) ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet 14, 2387-2398.

Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li Q, Holzinger E, Karyadi D et al. (2016) REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet 99, 877-885.

Hruska KS, LaMarca ME, Scott CR & Sidransky E (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 29, 567-583.

Horowitz M, Tzuri G, Eyal N, Berebi A, Kolodny EH, Brady RO, Barton NW, Abrahamov A & Zimran A (1993) Prevalence of nine mutations among Jewish and non-Jewish Gaucher disease patients. Am J Hum Genet 53, 921-930.

Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, Cohen IJ, Tayebi N & Sidransky E (2000) Analysis and classification of 304 mutant alleles in patients with type 1 anti type 3 gaucher disease. Am J Hum Genet 66, 1777-1786.

Wei RR, Hughes H, Boucher S, Bird JJ, Guziewicz N, Van Patten SM, Qiu H, Pan CQ & Edmunds T (2011) X-ray and biochemical analysis of N370S mutant human acid β-glucosidase. J Biol Chem 286, 299-308.

Ohashi T, Hong CM, Weiler S, Tomich JM, Aerts JMFG, Tager JM & Barranger JA (1991) Characterization of human glucocerebrosidase from different mutant alleles. J Biol Chem 266, 3661-3667.

Liou B (2006) Analyses of variant acid beta-glucosidases: effects of Gaucher disease mutations. J Biol Chem 281, 4242-4253.

Grabowski GA, Zimran A & Ida H (2015) Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry. Am J Hematol 90, S12-S18.

Alfonso P, Aznarez S, Giralt M, Pocovi M & Giraldo P (2007) Mutation analysis and genotype/phenotype relationships of Gaucher disease patients in Spain. J Hum Genet 52, 391-396.

Colella P, Ronzitti G & Mingozzi F (2018) Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev 8, 87-104.

Meikle PJ, Brooxs DA, Ravenscroft EM, Yan M, Williams RE, Jaunzems AE, Chataway TK, Karageorgos LE, Davey RC, Boulter CD et al. (1997) Diagnosis of lysosomal storage disorders: evaluation of lysosome-associated membrane protein LAMP-1 as a diagnostic marker. Clin Chem 43, 1325-1335.

Klein AD, Ferreira NS, Ben-Dor S, Duan J, Hardy J, Cox TM, Merrill AH & Futerman AH (2016) Identification of modifier genes in a mouse model of Gaucher disease. Cell Rep 16, 2546-2553.

Jakóbkiewicz-Banecka J, Gabig-Cimińska M, Banecka-Majkutewicz Z, Banecki B, Węgrzyn A & Wȩgrzyn G (2014) Factors and processes modulating phenotypes in neuronopathic lysosomal storage diseases. Metab Brain Dis 29, 1-8.

Goker-Alpan O, Hruska KS, Orvisky E, Kishnani PS, Stubblefield BK, Schiffmann R & Sidransky E (2005) Divergent phenotypes in Gaucher disease implicate the role of modifiers. J Med Genet 42, 1-7.

Weinstein JJ, Goldenzweig A, Hoch S & Fleishman SJ (2020) PROSS 2: a new server for the design of stable and highly expressed protein variants. Bioinformatics 37, 123-125.

Zahradník J, Kolářová L, Peleg Y, Kolenko P, Svidenská S, Charnavets T, Unger T, Sussman JL & Schneider B (2019) Flexible regions govern promiscuous binding of IL-24 to receptors IL-20R1 and IL-22R1. FEBS J 286, 3858-3873.

Frey S & Görlich D (2014) A new set of highly efficient, tag-cleaving proteases for purifying recombinant proteins. J Chromatogr A 1337, 95-105.

Aricescu AR, Lu W & Jones EY (2006) Biological crystallography A time-and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D 62, 1243-1250.

Meivar-Levy I, Horowitzt M & Futerman AH (1994) Analysis of glucocerebrosidase activity using N-(1-[14C] hexanoyl)-D-erythro-glucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease. Biochem J 303, 377-382.

Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL et al. (2007) Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J 5, 579-590.

Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA & Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8, 2281-2308.

Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O et al. (2013) DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31, 827-832.

Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, Sullender M, Ebert BL, Xavier RJ & Root DE (2014) Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol 32, 1262-1267.

Ciron C, Cressant A, Roux F, Raoul S, Cherel Y, Hantraye P, Déglon N, Schwartz B, Barkats M, Heard JM et al. (2009) Human α-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and biodistribution. Hum Gene Ther 20, 350-360.

Shipley MM, Mangold CA & Szpara ML (2016) Differentiation of the SH-SY5Y human neuroblastoma cell line. J Vis Exp 53193.

Kim JL, Ben-Dor S, Rosenfeld-Gur E & Futerman AH (2021) A novel C-terminal DxRSDxE motif in ceramide synthases involved in dimer formation. J Biol Chem 298, 101517.

Sidransky E, Bottler A, Stubblefield B & Ginns EI (1994) DNA mutational analysis of type 1 and type 3 gaucher patients: how well do mutations predict phenotype? Hum Mutat 3, 25-28.